Table 2.

ORs and 95% CIs for occupational lifetime exposure to high molecular weight agents (IgE mediated) and type of lymphoma in Spain

No. subjects* exposed/nonexposedOR (95% CI)
Controls79/470Reference
All lymphomas69/4490.84 (0.58-1.23)
    Hodgkin's lymphoma9/502.27 (0.93-5.50)
        Nodular sclerosis7/323.22 (1.14-9.09)
        Lymphocyte predominance, mixed cellularity, not otherwise specified2/180.97 (0.20-4.93)
    B-cell lymphomas53/3620.75 (0.50-1.12)
        Chronic lymphocytic leukemia15/980.65 (0.33-1.25)
        Lymphoplasmacytic lymphoma1/150.39 (0.05-3.20)
        Splenic marginal zone lymphoma6/171.79 (0.57-5.62)
        Plasma cell myeloma12/650.90 (0.44-1.85)
        Marginal zone B-cell lymphoma3/250.94 (0.25-3.55)
        Follicular lymphoma7/351.04 (0.41-2.65)
        Diffuse large B-cell lymphoma7/790.46 (0.19-1.09)
        Other B-cell lymphoma2/280.45 (0.10-2.05)
    T-cell lymphoma7/370.83 (0.33-3.76)
        Mycosis fungoides/Sezary6/161.60 (0.53-4.84)
        Other T-cell1/210.21 (0.03-1.66)
  • * Five controls and one case could were excluded because of missing data on occupational exposure category.

  • Each lymphoma subgroup is compared with all controls, ignoring in each model all other types of lymphoma. ORs are adjusted for age (in 5 groups; 10 groups for Hodgkin's lymphoma due to the bimodal age pattern), sex, area (three hospitals), and four other occupational exposure groups (low molecular weight agents, bioaerosols, mixed exposures, and other possible asthma-related exposures).